Financial data from stock market websites like Yahoo Finance or Bloomberg

Biohaven Achieves Positive Results in Pivotal Study of Troriluzole for SCA, Stock Surges as FDA Approval Sought

Sep 23, 2024, 12:28 PM

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) has achieved positive topline results in a pivotal study of troriluzole for the treatment of Spinocerebellar Ataxia (SCA), an ultra-rare genetic disease that affects the nervous system. The drug demonstrated statistically significant superiority on nine consecutive, prespecified primary and secondary endpoints. Patients treated with troriluzole showed a 50-70% slowing of disease progression, equating to a 1.5-2.2 years delay over a three-year period. This progress has led to a 16.4% pre-market increase in Biohaven's stock price. The company plans to seek FDA approval for troriluzole after a previous setback last year when the FDA refused to review the asset. The trial data has allayed investor concerns, sending shares up more than 12% during trading.